
Mark Horowitz @markhoro.bsky.social
@markhoro
Followers
12K
Following
10K
Media
140
Statuses
5K
Trainee psychiatrist/Researcher @NELFT @UCLPsychiatry (honorary) . Maudsley Deprescribing Guidelines: https://t.co/MdD00q9Yd1 (US) https://t.co/9eUVpPj52p (UK)
London
Joined April 2013
Well explained here.
According to @markhoro, @sameerjauhar will publish an article tomorrow calling for antidepressant withdrawal to be deemphasised in clinical guidelines. This is a huge gut punch for those of us in the prescribed harm community who are trying to raise awareness about the risks of.
4
3
17
RT @EikoFried: Psychedelic science largely ignored problem of unblinding, dramatically inflating effect sizes (not even *assessed* in most….
0
101
0
It seems as usual I was too charitable and gave the benefit of the doubt too easily: the irrelevance of the short term studies that authors focused on was not highlighted. Instead they are calling for changes to guidelines to reflect that withdrawal is barely a thing. Disturbing.
Good to see Dr Jauhar's awareness of the general irrelevance of short term, drug company conducted studies in understanding the public health issue of high risk of withdrawal for millions of long-term users. Hope these measured thoughts will be in paper as well.
10
12
63
RT @atomicaceso: Sameer Jauhar’s pharma-backed paper dismissing antidepressant withdrawal based on short-term trials is academic gaslightin….
0
20
0
RT @lizctucker: In my latest podcast @LauraDelano reveals the reality of being diagnosed as bipolar at just 14; the cocktail of drugs she w….
0
10
0
RT @petrie_caroline: @markhoro I don’t think I can take it, I remember the last round of Big Pharma push back, the minimising of harms and….
0
2
0
More and more people are becoming aware of the trick being played on the public. Such an incredible amount of effort expended to save face, with such little regard for the effect on the health of so many people.
Mark highlights a major flaw in much of the existing research on antidepressant withdrawal: it focuses primarily on short-term use. This is deeply problematic given that millions of people are now taking antidepressants long-term and the risk of severe, protracted withdrawal.
4
18
78
Good to see Dr Jauhar's awareness of the general irrelevance of short term, drug company conducted studies in understanding the public health issue of high risk of withdrawal for millions of long-term users. Hope these measured thoughts will be in paper as well.
I do not have the ability to predict the future. Apparently some do. Reasonable point regarding length of studies. Happy to address this. I do not presume my work has relevance to anyone – that is their decision, not mine. Shanti.
2
13
42